mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Provider Training and Adherence Assistance in Two High Priority Settings
OMB # 0920-1428
Feb 5, 2024
Summary of Changes
We are requesting a non-substantial change to the information collection request (ICR) for the mChoice study (OMB #0920-1428).
We are making the following changes:
1. Updating the demographic questions related to sex and gender in the study instruments.
2. Adding an emtricitabine assay to the patient consent form
3. Adding a single question about when the last PrEP medication was taken to the baseline and quarterly assessments
4. Adding an explanatory statement to the app onboarding guide about logging out of the app.
In the time since the ICR was developed, the recipients were informed of the findings of a community advisory panel held to advise on the framing of questions about sex and gender in research, especially considering how to best address these questions for youth. To be responsive to these recommendations and to align with local best practices in language around sex and gender, the mChoice study team has updated the sexual orientation and gender identity questions in the survey instruments. Updating the framing of these questions also aligns with “Recommendations on the best practices for the collection of sexual orientation and gender identity data on federal statistical surveys” released by the White House in January 2023.1 This change is responsive to input from community stakeholders and aligns with the goals and plans of this project.
Tables:
The changes to demographic questions related to sex and gender are outlined in Table 1 below.
The changes to the patient consent form are outlined in Table 2 below.
The change to the baseline and quarterly assessments is outlined in Table 3 below.
The change to the app onboarding guide is outlined in in Table 4 below.
There are no changes to the burden table, SSA, SSB, or other attachments.
Table 1. Summary of Changes to Demographic Questions Related to Sex and Gender in Survey Instruments (Att 4i_Provider Pre-Training Assessment; Att 4a_Patient Screener)
Original Question |
Change Proposed |
Reason for Change Proposed |
Which of the following BEST represents how you think about yourself?
|
Which of the following BEST represents how you think about yourself?
|
Key stakeholder input, project goals |
Do you currently describe yourself as male, female, or transgender?
|
[If American Indian or Alaskan Native is not checked] How do you currently describe yourself? (Check all that apply)
[If American Indian or Alaskan Native is checked] How do you currently describe yourself? (Check all that apply)
|
Key stakeholder input, project goals |
Beyond the gender identities listed above, are there any other identities that you would use to describe yourself? (Select all that apply)
|
None |
Removed as redundant with changes to the prior question (outlined in the row above). |
What sex were you assigned at birth, on your original birth certificate?
|
What sex were you assigned at birth, on your original birth certificate?
|
Key stakeholder input, project goals |
Table 2. Summary of Changes to the Patient Consent Form (Att 5b_Patient Consent Form)
Location |
Change |
Reason for Change |
Page 3 |
Added emtricitabine PrEP to types of PrEP |
Addition of emtricitabine assay to study |
Page 6 |
Added NanoComposix Laboratory to study collaborators |
Addition of the emtricitabine assay laboratory |
Page 7 |
Added de-identified sample processing to the urine test section |
Addition of information about emtricitabine assay processing |
Table 3. Summary of Changes to Baseline and Quarterly Assessments (Att 4c_Patient Baseline Assessment; 4d_Patient Quarterly Assessment)
Location |
Change |
Reason for Change |
Baseline assessment, Page 13, item F4b |
Added question “When did you last take a PrEP pill?” |
Provide context for laboratory studies that measure levels of tenofovir and emtricitabine. |
Quarterly assessment, Page 18, item F4b |
Added question “When did you last take a PrEP pill?” |
Provide context for laboratory studies that measure levels of tenofovir and emtricitabine. |
Table 4. Summary of Changes to the App Onboarding Guide (4e_CleverCap App Setup)
Location |
Change |
Reason for Change |
Page 1 |
Added text: “It is important to note that once you log into the app, there is no automatic time out. You must manually log out of the app through use of the side menu bar every time you want to be logged out of the app to maintain confidentiality.”
|
Ensure participants are aware of how to log out/maintain confidentiality by requiring sign in screen |
Attachments:
Att 4a_Patient Screener_TRACK CHANGES
Att 4a_Patient Screener_CLEAN
Att 4i_Provider Pre-Training Assessment_TRACK CHANGES
Att 4i_Provider Pre-Training Assessment_CLEAN
Att 4c_Patient Baseline Assessment_TRACK CHANGES
Att 4c_Patient Baseline Assessment_CLEAN
Att 4d_Patient Quarterly Assessment_TRACK CHANGES
Att 4d_Patient Quarterly Assessment_CLEAN
Att 4e_CleverCap App Setup_TRACK CHANGES
Att 4e_CleverCap App Setup_CLEAN
Att 5b_Patient Consent Form_TRACK CHANGES
1 The White House. Recommendations on the best practices for the collection of sexual orientation and gender identity data on federal statistical surveys. Jan 2023. Available: https://www.whitehouse.gov/wp-content/uploads/2023/01/SOGI-Best-Practices.pdf. Accessed: Nov 2 2023.
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Debra Karch |
File Modified | 0000-00-00 |
File Created | 2024-11-20 |